Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20452/pamw.16024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antithrombotic therapy impact on patency and bleeding complications of arteriovenous graft placement in dialysis patients.
Vasa
January 2025
Department of Vascular Surgery, Larissa University Hospital, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Arteriovenous grafts (AVG) can be the only bailout solution for patients who require kidney replacement therapy but are unsuitable for arteriovenous fistula (AVF) creation. Currently, high-level evidence on the effectiveness and safety of antithrombotic therapy in AVG patients is scarce. Following the PICO (patient; intervention; comparator; outcome) model and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a data search of the English literature in PubMed, SCOPUS, Central Cochrane was conducted, until March 1st, 2023 (PROSPERO Protocol Number: CRD42023401785).
View Article and Find Full Text PDFSystematic Analysis of the Design, Methodology and Patient Population Characteristics of the Pediatric Direct Oral Anticoagulant (DOAC) Trials of Venous Thromboembolism Treatment.
J Thromb Haemost
January 2025
Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
Introduction: The pediatric direct oral anticoagulation (DOAC) trials provide an opportunity to evaluate and characterize challenges in their design and execution to inform future antithrombotic trials.
Objective: To perform a systematic review of pediatric DOAC trials for the treatment of venous thromboembolism to critically appraise their methodology and understand the feasibility and challenges.
Methods: Systematic search of MEDLINE, EMBASE, the Cochrane Library and ClinicalTrials.
Peak and Trough Concentrations of Apixaban and Rivaroxaban in Adult Patients: A Systematic Review and Meta-Analysis.
J Thromb Haemost
January 2025
Center for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Electronic address:
Article Synopsis
- Apixaban and rivaroxaban, both factor Xa inhibitors, are used for treating conditions like venous thromboembolism and preventing strokes in atrial fibrillation patients, but their optimal concentration levels in real-world settings are not well understood.
- Researchers conducted a meta-analysis of 16 observational studies to establish average peak and trough concentrations for these medications, involving a total of 2,375 patients.
- The study found that average peak concentrations for apixaban and rivaroxaban were within expected ranges, and certain factors like age and creatinine clearance were found to influence these concentrations.
Spinal Anesthesia in Elderly Patients With Femoral Neck Fractures on Apixaban Therapy: A Case Series.
A A Pract
January 2025
From the Department of Anesthesiology, Sheba Medical Center, Ramat Gan, Israel.
This case series reviews surgeries involving elderly patients with femoral neck fractures on apixaban who underwent spinal anesthesia (SA) within 72 hours of their last dose. Despite patients being on anticoagulation, no neurological complications occurred, suggesting SA may be practical in cases where the benefits of timely surgery outweigh the potential risks, including apixaban discontinuation for a period of less than the recommended 72 hours with detectable levels of the drug remaining in the plasma. Quantitative apixaban measurements offered useful anticoagulation status insights, though safe thresholds remain undefined.
View Article and Find Full Text PDFImpact of Apixaban Lead-In Therapy Duration After Parenteral Anticoagulation on Bleeding in Patients Treated for Venous Thromboembolism.
J Pharm Pract
January 2025
Department of Pharmacy, Veterans Affairs Hospital, Memphis, TN, USA.
Venous thromboembolism (VTE) treatment with apixaban uses a higher 10 mg twice daily regimen for 7 days (lead-in therapy). But, in patients with initial parenteral anticoagulation treatment or those with higher bleeding risk, clinicians may not always adhere to the full 7-day lead-in duration. This retrospective cohort study included adult patients admitted to the Veterans Affairs Health care System from January 2011 to April 2022, who received at least 24 hours of parenteral anticoagulation followed by lead-in apixaban therapy for VTE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!